Yahoo · Sep 11, 2026
TFX vs. PEN: Which Stock Is the Better Value Option?
TFX vs. PEN: Which Stock Is the Better Value Option?
NYSE · TFX
Teleflex Incorporated
Healthcare · Medical - Instruments & Supplies
$129.02
Down-$0.46 (-0.36%)
Updated Sep 16, 2026, 3:35 PM
SID Score
4.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 5.63B
- P/E ratio
- -17.18
- Dividend yield
- 1.05%
- 52-week range
- $100.18 – $145.00
- Volume
- 803.75K
- Avg. volume
- 634.31K
Price performance
TFX price history
1M range · 20 trading sessions · Daily adjusted prices
TFX closed at $129.02 after 20 trading sessions, down 2.20% for the selected period.
- Last close
- $129.02
- Period change
- -2.20%
- Period low
- $129.02
- Period high
- $142.05
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $130.40 | $130.40 | $126.18 | $129.02 | 803.75K |
| Sep 14, 2026 | $132.68 | $134.27 | $129.51 | $130.30 | 976.92K |
| Sep 11, 2026 | $133.23 | $134.09 | $128.98 | $130.99 | 572.75K |
| Sep 10, 2026 | $134.96 | $135.0825 | $130.985 | $132.00 | 763.24K |
| Sep 9, 2026 | $139.54 | $139.54 | $135.315 | $135.72 | 487.04K |
| Sep 8, 2026 | $136.66 | $139.105 | $134.775 | $137.00 | 496.12K |
| Sep 4, 2026 | $138.70 | $140.59 | $137.35 | $138.36 | 464.47K |
| Sep 3, 2026 | $140.01 | $143.23 | $138.64 | $139.96 | 704.9K |
| Sep 2, 2026 | $140.56 | $144.16 | $138.10 | $140.97 | 728.07K |
| Sep 1, 2026 | $140.19 | $143.05 | $135.20 | $140.48 | 565.01K |
| Aug 31, 2026 | $137.95 | $142.42 | $137.88 | $142.05 | 653.15K |
| Aug 28, 2026 | $137.35 | $140.57 | $137.35 | $139.67 | 429.36K |
| Aug 27, 2026 | $136.55 | $138.51 | $136.55 | $137.71 | 370.58K |
| Aug 26, 2026 | $139.14 | $140.17 | $137.955 | $138.74 | 533.77K |
| Aug 25, 2026 | $138.01 | $140.57 | $136.32 | $140.18 | 382.41K |
| Aug 24, 2026 | $138.87 | $140.275 | $137.71 | $138.31 | 645.09K |
| Aug 21, 2026 | $133.31 | $139.21 | $133.31 | $138.83 | 641.97K |
| Aug 20, 2026 | $135.12 | $137.28 | $134.88 | $134.96 | 297K |
| Aug 19, 2026 | $132.63 | $136.80 | $132.63 | $135.86 | 459.65K |
| Aug 18, 2026 | $133.50 | $136.04 | $130.89 | $131.92 | 872.41K |
Latest TFX news
The latest Smart Investors Daily articles mentioning TFX.
Stock researchCompany · Overview
TFX research
Overview
Company profile and research snapshot.
Company profile
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $129.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | Needham | Buy | — |
| Aug 11, 2026 | UBS | Neutral | — |
| Aug 10, 2026 | Truist Securities | Hold | — |
| Aug 7, 2026 | Piper Sandler | Overweight | — |
| Jul 31, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 9, 2026
Surgical Equipment & Consumables - Specialty Stocks Q2 Earnings Review: Teleflex (NYSE:TFX) Shines
Looking back on surgical equipment & consumables - specialty stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Teleflex (NYSE:TFX) and its peers.
Yahoo · Sep 8, 2026
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
WAYNE, Pa., September 08, 2026--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026.
Yahoo · Sep 4, 2026
Should You Continue to Hold TMO Stock in Your Portfolio?
Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
